TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03829891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beinaglutide
Description: 1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beinaglutide
Description: 1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine
Description: 1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine
Description: 1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )
Study: NCT02004535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Description: The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
Study: NCT02996591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block
Study: NCT01687803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to \~60 min/day for 6 days/week (\~360 minutes per week).
Study: NCT02996591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed
Study: NCT03921112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine tools
Description: chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
Study: NCT01820260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02996591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 45-60 mg of 1.5% mepivacaine for spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia
Study: NCT01820260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01370733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEST-1 (NeoSync EEG Synchronized TMS)
Description: The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
Study: NCT05383794

Intervention type: OTHER
Intervention: Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
Description: Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
Study: NCT01687803

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
Study: NCT01732783

Intervention type: OTHER
Intervention: Panitumumab + Chemotherapy
Description: Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
Study: NCT00845182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
Study: NCT00075270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Active Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016 (Lapatinib)
Description: Oral GW572016 Lapatinib
Study: NCT03361644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Continuous Training
Description: Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
Study: NCT00767182

Intervention type: OTHER
Intervention: blood sample
Description: biological markers evaluated : D-Dimer, sEPCR
Study: NCT04661098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (Darwish hymenotomy technique)
Description: Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
Study: NCT00464243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volinanserin
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT00159822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours
Study: NCT00635024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 2.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 16 mg/m\^2
Study: NCT02727543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medisafe
Description: Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements
Study: NCT04164693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: patients began to use low molecular weight heparin or warfarin sodium tablets.

Intervention type: OTHER
Group type: OTHER
Intervention: non anticoagulant therapy group
Description: no anticoagulant was used after operation.
Study: NCT04636853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)
Description: A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control.
Study: NCT01221740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savella
Description: The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8
Study: NCT04329689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Septal myectom
Description: The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary
Study: NCT02755792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calligraphy Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iPad Training
Study: NCT02728973

Intervention type: OTHER
Intervention: ERAS program
Description: The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
Study: NCT00005866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: both arms per published schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: day 0

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: both arms: 1200 cGy total dose (6 x 200 fractions)
Study: NCT02331160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rebozo
Description: Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
Study: NCT03486314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion.
Study: NCT05152355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microgram/Puff, HFA MDI
Description: Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 100 microgram/Actuation Powder for Inhalation
Description: Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
Study: NCT00930410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
Description: Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
Study: NCT02764879

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: omega3 received 2 times daily-for 6 months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and root planing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo soft gelatin capsules
Description: placebo soft gelatin capsules received 2 times daily-for 6 months
Study: NCT03830281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-Rapid Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT04194177

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation during robotic surgery
Description: protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical ventilation during robotic surgery
Description: protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
Study: NCT00805207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucocorticoid
Description: Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No treatment with studies performed 31 to 72 days apart
Study: NCT02249052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AA4500
Description: Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT01595217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI
Description: diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI
Description: diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
Study: NCT01523821

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
Description: Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
Description: Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
Description: Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
Study: NCT02945592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cueing
Study: NCT03441126

Intervention type: OTHER
Intervention: Multicenter Quality Improvement program
Description: Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
Study: NCT04567784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
Study: NCT02179840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation adjustment
Description: Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation adjustment
Description: Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
Study: NCT00845182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Exenatide
Description: Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
Study: NCT03086343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib
Description: 15 mg extended release tablet
Study: NCT03086343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: 15 mg extended release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib
Description: 15 mg extended release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: 15 mg extended release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for upadacitinib
Description: Film-coated tablet
Study: NCT00886470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.